Latest articles on AI, technology, and software development.
GLP-1 receptor agonists were approved to treat diabetes and then became a blockbuster weight-loss category. Now researchers are finding the drugs appear to reduce addiction, depression, and possibly neurodegeneration — and no one fully understands why.
Aging biology has moved from philosophy to molecular targets. Senolytics are clearing senescent cells in human trials, Altos Labs began safety testing in 2025, and epigenetic clocks can now measure how fast you're aging — not just how old you are.
Quantum computing has promised transformative results for decades while struggling with a fundamental obstacle: physical qubits are fragile, error-prone, and decohere in microseconds. A series of landmark results published in 2025 and early 2026 suggest the field has genuinely turned a corner on error correction — the core technical problem that separates useful quantum computers from the expensive experiments of the last decade.
Noland Arbaugh became the first human to receive a Neuralink implant in January 2024, controlling a computer cursor with his thoughts. He's one of several patients across competing companies demonstrating that invasive BCIs work at a basic level. The harder questions — scale, safety, longevity, and what these devices can actually do — are now the frontline.
Researchers at the University of Cambridge used AI to identify a structural region conserved across the entire coronavirus family — from SARS-CoV-2 and its variants to MERS and bat coronaviruses not yet seen in humans. The resulting experimental pan-coronavirus vaccine has now completed a Phase I human trial in the UK, demonstrating a safety profile that clears the path to larger efficacy studies. Here is what the science actually showed, and what it does not yet prove.
GLP-1 receptor agonists were approved for type 2 diabetes. Then they turned out to reduce cardiovascular events, treat addiction, and slow cognitive decline. The class of drug may be the most consequential pharmacological discovery since statins.
DeepMind's AlphaFold 3 can predict the structure of proteins, DNA, RNA, and small molecules together. A year after broad access opened, drug discovery labs and academic researchers are starting to show what that capability actually unlocks.
Google's Willow chip demonstrated for the first time that adding more qubits actually reduces errors — the central unsolved problem of quantum computing. The physics is revolutionary; practical applications are still a decade away.
In 2025, the first CRISPR therapy generated $115 million in commercial revenue. An infant received a personalized gene edit designed and approved in six months. The first in vivo CRISPR treatment succeeded in Phase 3. After three decades of molecular biology, the editing era has genuinely arrived — with all the complexity that implies.
AlphaFold 3 didn't just improve protein structure prediction — it modeled the full molecular ecosystem drugs operate in. Multiple clinical pipelines are now running on AI-designed targets. The first approved AI drug may be closer than the industry's 10-year timeline suggests.
Google DeepMind's AlphaFold 3 has crossed a critical threshold in binding affinity prediction, with new benchmarks showing it matches or beats traditional experimental screening on 73% of tested drug targets — reshaping how pharmaceutical companies spend their first two years of R&D.
Google DeepMind's AlphaFold 3 has crossed a critical threshold in binding affinity prediction, with new benchmarks showing it matches or beats traditional experimental screening on 73% of tested drug targets — reshaping how pharmaceutical companies spend their first two years of R&D.